Hydroxy-methyl-glutaryl-coenzyme A reductase (HMGCR), the rate-limiting enzyme of cholesterol synthesis, was recently identified as one candidate target involved in elevated AML-EV release during chemotherapy [48]. Here, HMGCR is linked to acute myeloid leukemia.